英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

inhabitation    音标拼音: [ɪnh,æbət'eʃən]
n. 居住;箩息

居住;箩息

inhabitation
n 1: the act of dwelling in or living permanently in a place
(said of both animals and men); "he studied the creation
and inhabitation and demise of the colony" [synonym:
{inhabitancy}, {inhabitation}, {habitation}]


请选择你想看的字典辞典：
单词字典翻译
Inhabitation查看　Inhabitation　在百度字典中的解释百度英翻中〔查看〕
Inhabitation查看　Inhabitation　在Google字典中的解释Google英翻中〔查看〕
Inhabitation查看　Inhabitation　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Tirzepatide: Uses, Dosage, Side Effects Warnings - Drugs. com
    Zepbound (tirzepatide) is FDA-approved for weight loss in adults with obesity or who are overweight and have weight-related medical problems or OSA Zepbound helps you to lose weight and maintain weight loss and should be combined with diet and exercise
  • How Much Weight Can I Expect to Lose on Tirzepatide?
    This study looked specifically at people using Tirzepatide for weight loss who did not have diabetes The study lasted for 72 weeks (about a year and a half), and it gives us the best and most reliable information we have The results were so impressive that they have set a whole new standard for what’s possible with medical weight loss
  • Can Tirzepatide Help You Lose Weight? - GoodRx
    Along with diet and exercise, tirzepatide can lead to significant weight loss — an average of 15% to 20% (34 lbs to 48 lbs) But tirzepatide for weight loss is only recommended for people who meet certain BMI criteria
  • Tirzepatide adds significant weight loss even after lifestyle . . .
    After losing at least 5% of body weight after 12 weeks of diet and exercise, patients who took the dual glucagon-like peptide 1 and gastric inhibitory polypeptide receptor agonist tirzepatide lost an additional 18 4% of weight, according to results from the phase 3 SURMOUNT-3 trial
  • Tirzepatide: How it Works, Pros and Cons, Weight Loss . . .
    Weight loss among those who received tirzepatide was an average loss of 15% to 20% of their starting body weight over 72 weeks, about 16 5 months That is a mean weight loss of 34 lbs to 48 lbs The placebo subjects, who injected no medicine, had an average of only 3% weight loss
  • Tirzepatide for Weight Loss: Results, Side Effects Safety
    Tirzepatide is a prescription medication used for weight loss and to treat Type 2 diabetes in adults A weekly injection, tirzepatide acts as a dual agonist, meaning it mimics two gut peptides: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
  • Tirzepatide Weight Loss: How Users Are Dropping 50+ Pounds in . . .
    These results outperform older medications like semaglutide (Ozempic Wegovy), which typically produce 12–15% average weight loss How Tirzepatide Works with a Natural Weight Loss Plan Tirzepatide isn’t a magic bullet To get the best results—and avoid weight regain—it should be paired with healthy daily habits
  • Tirzepatide (Zepbound) for the Treatment of Obesity - AAFP
    Tirzepatide is highly effective and may be considered for patients desiring significant weight loss who are able to administer weekly subcutaneous injections
  • Efficacy and Safety of Tirzepatide on Weight Loss in Patients . . .
    The SURMOUNT trials further confirmed tirzepatide's weight loss effects, leading to its FDA approval as a treatment for weight management [7-10] While previous meta-analyses have explored tirzepatide's impact on weight loss in individuals with overweight or obesity, our meta-analysis offers distinct advantages
  • Effect of Tirzepatide on Maintenance of Weight Reduction
    FindingsAfter 36 weeks of open-label maximum tolerated dose of tirzepatide (10 or 15 mg), adults (n = 670) with obesity or overweight (without diabetes) experienced a mean weight reduction of 20 9%





中文字典-英文字典  2005-2009